Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Heart Age Could Help Revolutionise CVD Risk Management
Unilever and the World Heart Federation announce a joint initiative to promote awareness of Heart Age - a new, personally motivating way of expressing an individual"s risk of developing heart disease and stroke.
generic viagra online
Study Links Depressive Mood, Racial Disparities In Preterm Birth
Women who have depression symptoms prior to becoming pregnant are at an increased risk for having preterm births, with the risk twice as high for black women as for white women, according to a study in the Journal of Women"s Health, Reuters reports. For the study, Amelia Gavin of the University of Washington and colleagues examined the links between race, preterm birth and pre-pregnancy depressive mood among 555 women. The study used data collected from 1990-1996 as part of a larger, long-term investigation of heart disease risk.Researchers determined that 18.1% of the 249 black women in the study gave birth prior to 37 weeks" gestation, compared with 8.5% of the 306 white women in the study. The study also found that 9.4% of black women had pre-pregnancy symptoms of depressive mood, compared with 7.2% of white women. After researchers accounted for other factors associated with preterm birth, such as body weight and sociodemographic characteristics, black women"s risk remained more than twice that of white women.Gavin said, "The black-white disparity in preterm birth may be in part a consequence of different exposures to depressive mood prior to pregnancy." She said, "Reproductive outcomes must be viewed in light of women"s health over the entire life-course, as well as during pregnancy," adding that the study"s results suggest that "the experience of cumulative health disadvantages or "weathering"" might play a role in increased risk for preterm birth (Hendry, Reuters, 6/25).
News of the day
Alzheimer's Society Response To The Publication Of Revised NICE Guidance On Alzheimer's treatments
Thousands of people with Alzheimer"s will continue to be denied access to the only drug treatments for the disease following the publication of revised guidance by the NICE.
Endocrinology

Results From Trials Of DHA In Alzheimer's Disease And Age-Related Cognitive Decline

Results from two large studies using DHA, an omega 3 fatty acid, were reported at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD 2009) in Vienna. One of the trials was conducted by the Alzheimer"s Disease Cooperative Study (ADCS) supported by the U.S. National Institute on Aging (NIA), and the second by Martek Biosciences Corporation. The NIA trial lasted 18 months and was conducted in people with mild to moderate Alzheimer"s. Martek"s trial was six months, and was conducted in healthy people to see its effect on "age related cognitive decline" Both studies used Martek"s algal DHA. The results of the ADCS trial show no evidence for benefit in the studied population. The Martek trial showed a positive result on one test of memory and learning, but that study was in healthy older adultswith mild memory complaint, not people with Alzheimer"s or another dementia. The results need confirmation. "These two studies - and other recent Alzheimer"s therapy trials - raise the possibility that treatments for Alzheimer"s must be given very early in the disease for them to be truly effective," said William Thies, PhD, Chief Medical & Scientific Officer at the Alzheimer"s Association. "For that to happen, we need to get much better at early detection and diagnosis of Alzheimer"s." DHA (docosahexaenoic acid) is the most abundant omega 3 fatty acid in the brain. Previous animal studies and epidemiology in humans suggested that DHA may be beneficial in people with Alzheimer"s. The studies reported at ICAD 2009 were: -- Joseph Quinn, et al - A clinical trial of docosahexaenoic acid (DHA) for the treatment of Alzheimer"s disease. -- Karin Yurko-Mauro, et al - Results of the MIDAS Trial: Effects of Docosahexaenoic Acid on Physiological and Safety Parameters in Age-Related Cognitive Decline. The 2009 Alzheimer"s Association International Conference on Alzheimer"s Disease (ICAD 2009) brings together more than 3,000 researchers from 70 countries to share groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer"s disease and related disorders. ICAD 2009 will be held in Vienna, Austria at Messe Wien Exhibition and CongressCenter from July 11-16. The Alzheimer"s Association is the leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer"s disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer"s. For more information, visit www.alz.org. Alzheimer"s Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009